

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Ligget, Stephen B.

Application No.: To be assigned
Filed: May 25, 2001

Group No.: To be assigned
Examiner: To be assigned

For: POLYMORPHISMS IN THE 5' LEADER CISTRON OF THE BETA2-ADRENERGIC
RECEPTOR

Assistant Commissioner for Patents
Washington, D.C. 20231

FIRST PRELIMINARY AMENDMENT TO CLAIMS
(37 C.F.R. 1.121 and M.P.E.P. 714.09)

This application is the National Phase filing of PCT/US99/27963. This paper is filed to cancel claims. Prior to calculating the filing fee, it is respectfully requested that the claims be amended as indicated below.


IN THE CLAIMS

Please cancel claims 22, 24, and 25 without prejudice or disclaimer.

REMARKS

This amendment cancels claims in order to facilitate prosecution of the application. Should any questions arise, or if Applicant or Applicant's Attorney can facilitate examination of this Application, please contact the undersigned Attorney at the phone number below.

Respectfully submitted,



Gisela M. Field
Genaissance Pharmaceuticals, Inc.
Five Science Park
New Haven, CT 06511

Reg. No. 47,562
Tel. No. 203-786-3473

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Liggett, Stephen B.

Application No.: To be assigned
Filed: May 25, 2001

Group No.: To be assigned
Examiner: To be assigned

For: POLYMORPHISMS IN THE 5' LEADER CISTRON OF THE BETA2-ADRENERGIC RECEPTOR

Assistant Commissioner for Patents
Washington, D.C. 20231

SECOND PRELIMINARY AMENDMENT TO CLAIMS
(37 C.F.R. 1.121 and M.P.E.P. 714.09)

This application is the National Phase filing of PCT/US99/27963. This paper is filed to amend claims in response to the International Preliminary Examination Report (IPER) mailed on March 6, 2001 and to add new dependent claims to the current application. The accompanying first preliminary amendment cancels claims prior to the calculation of the filing fee. The additional claims presented herein are not taken into account when calculating the filing fee. Please charge any additional claims fees to our deposit account 50-1293 or credit any excess thereto.

IN THE CLAIMS

Please amend the following claims:

19. (amended) A method for determining the frequency of a B₂AR genotype or a B₂AR haplotype in a population, comprising
 - (a) determining the B₂AR genotype or the B₂AR haplotype pair for [the B₂AR 5' gene that is present in] each member of the population and
 - (b) calculating the frequency any particular B₂AR genotype or B₂AR haplotype is found in the population.
26. (amended) A method for predicting a patient's bronchodilating response to an agonist of B₂AR, which comprises determining the patient's genotype for the B₂AR 5'LC polymorphic site, wherein a patient who is homozygous T at this site is unlikely to exhibit a bronchodilating response to the agonist and a patient who contains a C at this site is likely to exhibit a bronchodilating response against the agonist.